- Home
- ODFL vs ARGX Comparison
ODFL vs ARGX Comparison
Compare ODFL & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODFL
- ARGX
- Stock Information
- Founded
- ODFL 1934
- ARGX 2008
- Country
- ODFL United States
- ARGX Netherlands
- Employees
- ODFL N/A
- ARGX N/A
- Industry
- ODFL Trucking Freight/Courier Services
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ODFL Industrials
- ARGX Health Care
- Exchange
- ODFL Nasdaq
- ARGX Nasdaq
- Market Cap
- ODFL 48.1B
- ARGX 40.4B
- IPO Year
- ODFL 1991
- ARGX 2017
- Fundamental
- Price
- ODFL $180.40
- ARGX $644.48
- Analyst Decision
- ODFL Hold
- ARGX Strong Buy
- Analyst Count
- ODFL 20
- ARGX 20
- Target Price
- ODFL $205.00
- ARGX $653.11
- AVG Volume (30 Days)
- ODFL 1.9M
- ARGX 229.4K
- Earning Date
- ODFL 02-05-2025
- ARGX 02-27-2025
- Dividend Yield
- ODFL 0.62%
- ARGX N/A
- EPS Growth
- ODFL N/A
- ARGX N/A
- EPS
- ODFL 5.48
- ARGX N/A
- Revenue
- ODFL $5,814,810,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- ODFL $6.38
- ARGX $73.18
- Revenue Next Year
- ODFL $9.86
- ARGX $55.26
- P/E Ratio
- ODFL $32.92
- ARGX N/A
- Revenue Growth
- ODFL N/A
- ARGX 85.56
- 52 Week Low
- ODFL $165.49
- ARGX $349.86
- 52 Week High
- ODFL $233.26
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- ODFL 36.77
- ARGX 49.33
- Support Level
- ODFL $198.68
- ARGX $637.15
- Resistance Level
- ODFL $209.61
- ARGX $652.23
- Average True Range (ATR)
- ODFL 6.74
- ARGX 12.63
- MACD
- ODFL -0.76
- ARGX -1.94
- Stochastic Oscillator
- ODFL 26.26
- ARGX 30.64
About ODFL Old Dominion Freight Line Inc.
Old Dominion Freight Line is the second-largest less-than-truckload carrier in the United States, with more than 250 service centers and 11,000-plus tractors. It is one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns are head and shoulders above its peers. Strategic initiatives revolve around boosting network density through market share gains and maintaining industry-leading service (including ultralow cargo claims) via steadfast infrastructure investment.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.